KRAS-dependent cancer cell growth is inhibited by disrupting phosphatidylserine transport to the plasma membrane by genetic knockdown of lipid exchangers ORP5 and ORP8 or by inhibition of PI4KIIIα. This evidence concerns the gene KRAS and cancer.